Iovance Biotherapeutics initiated at Piper Jaffray

Iovance Biotherapeutics initiated with an Overweight at Piper Jaffray. Piper Jaffray analyst Joseph Catanzaro started Iovance Biotherapeutics with an Overweight rating and $20 price target. The company has “clearly demonstrated the ability to produce a cell therapy with consistent and impressive efficacy in multiple solid tumor settings,” Catanzaro tells investors in a research note. He believes response rates of 30%-40% position Iovance for multiple potential approvals over the next five years that include melanoma, cervical cancer, and head and neck cancer.

https://thefly.com/landingPageNews.php?id=2898755